Opinion: Let the Market Dictate Drug Prices in China
Listen to the full version
China’s State Council recently issued new guidelines titled Several Opinions on Improving the Market-Driven Drug Pricing Mechanism. This directive dictates that the market should play the decisive role in resource allocation, while sharpening the government’s regulatory function. By proposing reforms across the entire life cycle, distribution channel and sector of the pharmaceutical industry, the policy seeks to invigorate market dynamics, maintain fair competition and act as a catalyst for growth — particularly for developers of innovative therapies. The aim is to foster a high-quality pharmaceutical sector while ensuring the public has access to premium, affordable drugs.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Save an extra $50. Introductory offer for new readers. Subscribe now.
- DIGEST HUB
Digest Hub
Back
- China’s State Council issued guidelines for market-driven drug pricing, emphasizing market allocation and government regulation across pharma lifecycle.
- 14 measures optimize initial prices for innovative drugs by novelty, allow real-world adjustments, and guide via insurance negotiations.
- Supports innovation (1/3 global pipeline, >200 approvals in 14th FYP, $130B+ 2025 overseas deals) and affordable access.
1. China's State Council issued "Several Opinions on Improving the Market-Driven Drug Pricing Mechanism," emphasizing market's decisive role in resource allocation and government's sharpened regulation across the pharmaceutical lifecycle, distribution, and sectors to boost dynamics, fair competition, growth for innovative therapies, high-quality sector, and affordable premium drugs [para. 1].
2. Historically, in 2015, the National Development and Reform Commission and six departments mandated market competition for drug prices (excluding narcotics/Class I psychotropics), alongside drug review overhaul, accelerating China's innovative pharma sector [para. 2].
3. The 2018 National Healthcare Security Administration establishment used insurance payments to guide prices, reducing costs for domestic breakthroughs in/outside insurance, benefiting patients; new guidelines align market efficiency with government proactivity, supporting/protecting/governing as needed [para. 3].
4. Prices act as "batons" for innovation, not just supply-demand signals; reforms ensure novel treatment costs reflect clinical value, enabling self-sustaining ecosystem evolution [para. 4].
5. China's drug innovation surged: from generics to hybrid/original models; ~1/3 global innovative drugs in development, oncology stars; 14th Five-Year Plan saw >200 approvals; 2025 overseas licensing deals topped $130 billion [para. 5].
6. Boom validates market-led pricing; guidelines refine policies in key segments, promote price discovery, keep critical prices reasonable, strengthen governance, focusing clinical value/accessibility [para. 6].
7. Of 14 measures, top is optimizing initial pricing for new innovative drugs: distinguishes highly innovative, modified new, off-patent generics with tailored support; top-tier get prices reflecting investments/risks, stable for period [para. 7].
8. Encourages diversified payments/rational pricing for accessibility and drugmaker sustainability, advancing China to global innovation powerhouse [para. 8].
9. Premium prices for novelties face real-world scrutiny; self-assessment allows post-launch adjustments based on outcomes, filtering true innovation [para. 9].
10. Medical insurance guides prices, balancing basics, welfare, incentives; negotiations for exclusive drugs consider initial price rationality, fund affordability, macroeconomics, clinical value; expands multi-tier insurance, commercial coverage [para. 10].
11. Market-led pricing reform needs systemic coordination beyond insurance; 15th Five-Year Plan (2026-2030) optimizes urgent approvals, commercial coverage; balances innovation subsidies/affordability, roots out failures like high prices/kickbacks/abuse; ensures accessible reasonable essential meds [para. 11].
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新